Help us: Donate
Follow us on:



INSERM – Remdesivir

Remdesivir, an antiviral drug that was initially developed for Ebola by the pharmaceutical company Gilead, has shown promise against COVID-19 [1, 2, 3]. It is an adenosine nucleotide analogue, which allows it to incorporate into viral RNA chains and cause premature termination of viral reproduction. It shows antiviral activity against filoviruses, paramyxoviruses, pneumoviruses, and pathogenic coronaviruses, including SARS-CoV and MERS-CoV [4].

INSERM has initiated DisCoVeRy, a Phase 3 clinical trial of remdesivir [5]. This study is a multi-center, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults. The study results should be published in March 2023.


  1. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., … & Xiao, G. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 30(3), 269-271.
  2. Ko, W. C., Rolain, J. M., Lee, N. Y., Chen, P. L., Huang, C. T., Lee, P. I., & Hsueh, P. R. (2020). Arguments in favor of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents, 105933.
  3. Martinez, M. A. (2020). Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrobial Agents and Chemotherapy.
  4. Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., … & Bannister, R. (2017). Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science translational medicine, 9(396).
  5. DisCoVeRy